F01 in the Treatment of Relapsed/Refractory Non-hodgkin ' s Lymphoma

Conditions: Non-Hodgkin ' s Lymphoma Interventions: Drug: After preconditioning with chemotherapy, F01 will be evaluated. Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials